Literature DB >> 18344728

Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial.

Jennifer R Glass1, Beth A Sproule, Nathan Herrmann, Usoa E Busto.   

Abstract

A randomized, controlled, crossover clinical study compared 14-night treatment with 15 mg temazepam, 50 mg diphenhydramine, and placebo in elderly individuals with insomnia (mean age, 73.9 years; range, 70-89 years). Primary outcome measures were subjective assessments of sleep recorded on sleep diaries. Secondary measures were the morning-after psychomotor impairment, using the digit symbol substitution task and the manual tracking task, and the morning-after memory impairment, using a free-recall procedure. Results showed sleep improvements with 15 mg temazepam compared with placebo-sleep quality (mean score, 3.3 +/- 0.9 vs 2.9 +/- 0.8; P = 0.03), total sleep time (6.9 +/- 1.0 hours vs 6.3 +/-1.3 hours; P = 0.02), number of awakenings (1.5 +/- 1.3 vs 2.0 +/- 1.2; P < 0.001), and sleep-onset latency (25 +/- 22 minutes vs 37 +/- 25 minutes; P = 0.03). Improvements were seen with diphenhydramine treatment compared with placebo on the number of awakenings only (mean, 1.7 +/- 1.1 vs 2.0 +/- 1.2; P < 0.05). Numbers of adverse events reported were similar after all treatments, although there was 1 fall during temazepam treatment. Findings indicate that temazepam is more effective than diphenhydramine when compared with placebo at the doses tested, although this advantage is mitigated by the risk of falls associated with temazepam use. The choice of agent to use in the elderly must consider these relative benefits and risks.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344728     DOI: 10.1097/JCP.0b013e31816a9e4f

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

Review 1.  Management of insomnia and long-term use of sedative-hypnotic drugs in older patients.

Authors:  Jacqueline M McMillan; Elizabeth Aitken; Jayna M Holroyd-Leduc
Journal:  CMAJ       Date:  2013-09-23       Impact factor: 8.262

2.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

3.  Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia: A Systematic Review of Efficacy and Safety.

Authors:  Larry Culpepper; Mark A Wingertzahn
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-31

Review 4.  Insomnia (primary) in older people.

Authors:  Cathy Alessi; Michael V Vitiello
Journal:  BMJ Clin Evid       Date:  2011-10-11

Review 5.  Insomnia in Elderly Patients: Recommendations for Pharmacological Management.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

6.  Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  Michael J Sateia; Daniel J Buysse; Andrew D Krystal; David N Neubauer; Jonathan L Heald
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

Review 7.  Insomnia.

Authors:  Daniel J Buysse
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272

8.  The assessment and management of insomnia: an update.

Authors:  Andrew D Krystal; Aric A Prather; Liza H Ashbrook
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

Review 9.  New Developments in Insomnia Medications of Relevance to Mental Health Disorders.

Authors:  Andrew D Krystal
Journal:  Psychiatr Clin North Am       Date:  2015-09-11

Review 10.  Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review.

Authors:  Judith Sys; Simon Van Cleynenbreugel; Mieke Deschodt; Lorenz Van der Linden; Jos Tournoy
Journal:  Eur J Clin Pharmacol       Date:  2019-12-14       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.